Oxford Immunotec Global PLC (OXFD) Downgraded by Zacks Investment Research to Sell
Oxford Immunotec Global PLC (NASDAQ:OXFD) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Saturday.
According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “
A number of other analysts have also issued reports on the company. BTIG Research set a $21.00 price objective on Oxford Immunotec Global PLC and gave the company a “buy” rating in a research note on Tuesday. Robert W. Baird reiterated a “buy” rating and set a $20.00 price objective on shares of Oxford Immunotec Global PLC in a research note on Wednesday. ValuEngine lowered Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research note on Tuesday. Piper Jaffray Companies decreased their price objective on Oxford Immunotec Global PLC from $26.00 to $19.00 and set an “overweight” rating on the stock in a research note on Tuesday. Finally, Cowen and Company reiterated a “buy” rating and set a $19.00 price objective on shares of Oxford Immunotec Global PLC in a research note on Thursday, September 28th. Three equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $19.75.
Shares of Oxford Immunotec Global PLC (OXFD) opened at $13.25 on Friday. Oxford Immunotec Global PLC has a fifty-two week low of $12.24 and a fifty-two week high of $19.51. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.72 and a quick ratio of 2.51.
Oxford Immunotec Global PLC (NASDAQ:OXFD) last released its quarterly earnings data on Tuesday, August 1st. The company reported ($0.32) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.32). Oxford Immunotec Global PLC had a negative return on equity of 38.42% and a negative net margin of 45.74%. The company had revenue of $26.10 million for the quarter, compared to analyst estimates of $25.05 million. During the same period in the previous year, the company posted ($0.29) EPS. The firm’s revenue for the quarter was up 35.9% compared to the same quarter last year. research analysts expect that Oxford Immunotec Global PLC will post -2.11 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This news story was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/11/04/oxford-immunotec-global-plc-oxfd-downgraded-by-zacks-investment-research-to-sell.html.
In related news, COO Peter Edwardson sold 22,371 shares of the business’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $17.70, for a total transaction of $395,966.70. Following the completion of the transaction, the chief operating officer now directly owns 102,644 shares in the company, valued at $1,816,798.80. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $13.35, for a total value of $40,050.00. Following the transaction, the director now owns 17,778 shares of the company’s stock, valued at $237,336.30. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 93,110 shares of company stock valued at $1,563,564. 8.11% of the stock is owned by company insiders.
A number of institutional investors have recently bought and sold shares of OXFD. American International Group Inc. grew its position in Oxford Immunotec Global PLC by 7.1% during the first quarter. American International Group Inc. now owns 13,668 shares of the company’s stock worth $212,000 after buying an additional 904 shares in the last quarter. Nationwide Fund Advisors grew its position in Oxford Immunotec Global PLC by 1.9% during the first quarter. Nationwide Fund Advisors now owns 13,765 shares of the company’s stock worth $213,000 after buying an additional 254 shares in the last quarter. Parkwood LLC grew its position in Oxford Immunotec Global PLC by 12.9% during the second quarter. Parkwood LLC now owns 12,799 shares of the company’s stock worth $215,000 after buying an additional 1,465 shares in the last quarter. Voya Investment Management LLC grew its position in Oxford Immunotec Global PLC by 16.0% during the second quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock worth $224,000 after buying an additional 1,845 shares in the last quarter. Finally, Alliancebernstein L.P. purchased a new position in Oxford Immunotec Global PLC during the second quarter worth about $247,000. Institutional investors and hedge funds own 79.21% of the company’s stock.
Oxford Immunotec Global PLC Company Profile
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.